Preclinical research suggests BH3 mimetic drugs that target antiapoptotic Bcl-2 family proteins can resensitize bladder cancer cells to cisplatin. The work reported sensitization in both patient-derived tumor spheroids and bladder cancer models, supporting a strategy of combining apoptosis pathway modulation with standard chemotherapy. The findings add to the growing effort to overcome resistance in bladder cancer, where platinum-based regimens often fail over time. By pointing to a specific mechanism—Bcl-2 family antiapoptotic activity—this line of research could guide biomarker selection in future translational studies. No clinical outcomes were reported in the summary provided, but the presence of patient-derived spheroid data strengthens the translational rationale for moving toward combination studies.